Humana Inc. (NYSE:HUM) Receives Average Recommendation of “Hold” from Brokerages

Shares of Humana Inc. (NYSE:HUM) have been assigned a consensus rating of “Hold” from the twenty-six brokerages that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $225.4783.

HUM has been the subject of several research analyst reports. The Goldman Sachs Group dropped their target price on shares of Humana from $215.00 to $158.00 and set a “sell” rating for the company in a research report on Friday, February 13th. Sanford C. Bernstein reissued an “outperform” rating and issued a $344.00 price target on shares of Humana in a research note on Tuesday, January 6th. Guggenheim lowered their price objective on shares of Humana from $312.00 to $252.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Wolfe Research lifted their price objective on Humana from $300.00 to $325.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. Finally, Zacks Research upgraded Humana from a “strong sell” rating to a “hold” rating in a report on Thursday, March 5th.

Insiders Place Their Bets

In other news, insider Sanjay K. Shetty acquired 810 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the acquisition, the insider owned 11,657 shares in the company, valued at $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is currently owned by insiders.

Institutional Trading of Humana

A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Revolve Wealth Partners LLC purchased a new position in Humana during the 4th quarter valued at about $202,000. Woodline Partners LP grew its holdings in Humana by 460.0% in the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock worth $2,697,000 after purchasing an additional 8,372 shares during the period. Sivia Capital Partners LLC increased its stake in shares of Humana by 53.7% during the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after purchasing an additional 452 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Humana by 25.1% during the second quarter. American Century Companies Inc. now owns 20,860 shares of the insurance provider’s stock valued at $5,100,000 after purchasing an additional 4,184 shares in the last quarter. Finally, J.W. Cole Advisors Inc. increased its stake in shares of Humana by 41.4% during the second quarter. J.W. Cole Advisors Inc. now owns 2,310 shares of the insurance provider’s stock valued at $565,000 after purchasing an additional 676 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

HUM opened at $166.36 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a market capitalization of $19.97 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 1.81 and a beta of 0.44. The stock’s 50 day moving average price is $189.58 and its 200-day moving average price is $237.60. Humana has a 52-week low of $163.11 and a 52-week high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm’s revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the firm posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities research analysts predict that Humana will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 27th. This represents a $3.54 annualized dividend and a dividend yield of 2.1%. Humana’s payout ratio is currently 36.05%.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.